Critical Comparison: Daiichi Sankyo (OTCMKTS:DSNKY) & Clene (NASDAQ:CLNN)

Clene (NASDAQ:CLNN – Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Insider & Institutional Ownership

23.3% of Clene shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Clene has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Daiichi Sankyo has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Clene and Daiichi Sankyo, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clene 1 0 6 0 2.71
Daiichi Sankyo 1 1 0 0 1.50

Clene presently has a consensus target price of $34.00, indicating a potential upside of 890.96%. Given Clene’s stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Daiichi Sankyo.

Profitability

This table compares Clene and Daiichi Sankyo’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clene -11,274.79% N/A -77.56%
Daiichi Sankyo 12.13% 16.31% 6.93%

Earnings and Valuation

This table compares Clene and Daiichi Sankyo”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clene $200,000.00 247.03 -$26.17 million ($2.60) -1.32
Daiichi Sankyo $14.10 billion 2.29 $1.72 billion $0.98 17.69

Daiichi Sankyo has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Daiichi Sankyo, indicating that it is currently the more affordable of the two stocks.

About Clene

(Get Free Report)

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines. Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.